期刊文献+

肠型胃黏膜内癌合并同时性肺转移癌一例 被引量:1

原文传递
导出
摘要 胃黏膜内癌指病变局限于胃黏膜肌内(黏膜上皮层、黏膜固有层、黏膜肌层),未侵透黏膜肌达黏膜下层。胃癌病理中Lauren分型是根据镜下病理的组织结构进行的分型,包括肠型胃癌、弥漫性胃癌和混合型胃癌。肠型胃癌起源于肠化生黏膜,镜下具有明显的腺管结构,瘤细胞呈柱状或立方形等特征,为发病率最高,预后最佳一种胃癌。对于分化良好的胃黏膜内癌血行转移,目前仅存在于极少数的个例报道,主要集中于异时性(超过半年以上)的肝转移病例,合并同时性肺转移癌的尚无报道病例。本文报告一例肠型胃黏膜内癌合并同时性肺转移癌的病例。
出处 《中华胃肠外科杂志》 CAS CSCD 北大核心 2019年第2期189-190,共2页 Chinese Journal of Gastrointestinal Surgery
基金 吉林省自然科学基金(20170414034GH).
  • 相关文献

参考文献3

二级参考文献86

  • 1Shigetaka Yoshinaga,Ichiro Oda,Satoru Nonaka,Ryoji Kushima,Yutaka Saito.Endoscopic ultrasound using ultrasound probes for the diagnosis of early esophageal and gastric cancers[J].World Journal of Gastrointestinal Endoscopy,2012,4(6):218-226. 被引量:21
  • 2操礼群.进展期胃癌术后早期双途径化疗的临床应用[J].实用肿瘤学杂志,2007,21(2):144-145. 被引量:4
  • 3Rebecca Siegel,Jiemin Ma,Zhaohui Zou,Ahmedin Jemal.Cancer statistics, 2014[J]. CA A Cancer Journal for Clinicians . 2014 (1) 被引量:48
  • 4Wasaburo Koizumi,Hiroyuki Narahara,Takuo Hara,Akinori Takagane,Toshikazu Akiya,Masakazu Takagi,Kosei Miyashita,Takashi Nishizaki,Osamu Kobayashi,Wataru Takiyama,Yasushi Toh,Takashi Nagaie,Seiichi Takagi,Yoshitaka Yamamura,Kimihiko Yanaoka,Hiroyuki Orita,Masahiro Takeuchi.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial[J]. Lancet Oncology . 2008 (3) 被引量:12
  • 5Peter C. Thuss-Patience,Albrecht Kretzschmar,Dmitry Bichev,Tillman Deist,Axel Hinke,Kirstin Breithaupt,Yasemin Dogan,Bernhard Gebauer,Guido Schumacher,Peter Reichardt.Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)[J].European Journal of Cancer.2011(15) 被引量:5
  • 6Florian Lordick,Yoon-Koo Kang,Hyun-Cheol Chung,Pamela Salman,Sang Cheul Oh,Gy?rgy Bodoky,Galina Kurteva,Constantin Volovat,Vladimir M Moiseyenko,Vera Gorbunova,Joon Oh Park,Akira Sawaki,Ilhan Celik,Heiko G?tte,Helena Melezínková,Markus Moehler.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6) 被引量:14
  • 7Lin Shen,Jin Li,Jianming Xu,Hongming Pan,Guanghai Dai,Shukui Qin,Liwei Wang,Jinwan Wang,Zhenzhou Yang,Yongqian Shu,Ruihua Xu,Lei Chen,Yunpeng Liu,Shiying Yu,Lilian Bu,Yongzhe Piao.Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J]. Gastric Cancer . 2015 (1) 被引量:7
  • 8David A. Guertin,David M. Sabatini.Defining the Role of mTOR in Cancer[J]. Cancer Cell . 2007 (1) 被引量:4
  • 9Van Cutsem E,Moiseyenko VM,Tjulandin S,et al.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology . 2006 被引量:4
  • 10Lieto Eva,Ferraraccio Francesca,Orditura Michele,Castellano Paolo,Mura Anna La,Pinto Margherita,Zamboli Anna,De Vita Ferdinando,Galizia Gennaro.Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Annals of Surgical Oncology . 2007 被引量:3

共引文献46

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部